newsfilter
← Earnings
Earnings Releases·

Profound Medical — Third Quarter 2026 Earnings Summary

  • Revenue surged 86% year-over-year to $9.8 million, driven by $5.7 million in capital equipment sales and $4.1 million in recurring revenue, while net loss narrowed 3% to $7.7 million and operating cash burn declined 48% year-over-year.
  • Full-year 2026 guidance remains intact with revenue projected at least $25.0 million and gross margin expected at 70% or higher, supported by a cash runway sufficient to fund operations for the next 12 months.
  • Strategic expansion includes a new distribution agreement with Cook Medical for U.S. TULSA-PRO systems, a co-education partnership with Telix Pharmaceuticals, and a 10.7 million covered lives increase in commercial payer engagement.
  • Leadership transition announced with Richard Fabian succeeding Arun Menawat as CEO effective January 14, 2027, while Matthew Sobczyk was appointed permanent CFO and Jason Mills joined the Board.
Company
PROFOUND MEDICAL CORP
Sector
Healthcare
Industry
Medical Devices